Mylan (MYL) Weakness on Headlines it May Have Misclassified EpiPen Under Medicaid

September 2, 2016 12:11 PM EDT

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

Mylan (NASDAQ: MYL) weaker on headlines it may have misclassified EpiPen under medicaid, according to lawmakers - Bloomberg. Shares down 3.1%.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Trader Talk

Add Your Comment